Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
ST Hulus: Subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. obtains the drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution
ST Huluwa announces that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution. This medication is used to treat chronic constipation and fecal impaction. The main active ingredients are polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate, developed by Norgine in the UK. The company has invested a total of RMB 762,100 in research and development. After obtaining the certificate, the product will further enrich the company’s product portfolio.